Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years

Journal of the Neurological Sciences

Volumn 201, Issue 1-2, 2002, Pages 71-77

  Chen, M ^a   Conway, K ^a   Johnson, K P ^a   Martin, R ^b   Dhib Jalbut, S ^a,c,d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c BALTIMORE VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Copaxone ; Glatiramer acetate; Immune deviation; Immunotherapy; Multiple sclerosis

Indexed keywords

GLATIRAMER;

ARTICLE; BYSTANDER EFFECT; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE; TH2 CELL;

BIOLOGICAL MARKERS; CROSS REACTIONS; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; PEPTIDE FRAGMENTS; PEPTIDES; TH2 CELLS;

EID: 0037105959     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(02)00201-0     Document Type: Article

References (31)

1. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide
2. Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer
3. Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE)
4. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses
5. Slagle sea. A pilot trial of COP 1 in exacerbating-remitting multiple sclerosis
6. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial
7. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. The copolymer 1 multiple sclerosis study group
8. The effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing remitting multiple sclerosis
9. T suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis
10. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1
11. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking
12. Treatment of Multiple sclerosis with copolymer-1 (Copaxone®): Implicating mechanism of Th1 to Th2/Th3 immune-deviation
13. Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis
14. Multiple sclerosis: Comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells
15. Mechanisms of immunomodulation by glatiramer acetate
16. Glatiramer acetate induces a Th2-biased response and cross-reactivity with myelin basic protein
17. Antigen-driven bystander suppression after oral administration of antigens
18. Direct binding of myelin basic protein and synthetic copolymer I to class II major histocompatibility complex molecules on living antigen-presenting cells- specificity and promiscuity
19. Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells
20. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules
21. Copolymer-1-induced inhibition of antigen-specific T cell activation: Interference with antigen presentation
22. Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1
23. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein
24. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of copolymer 1 on MOG-induced disease
25. Treatment of multiple sclerosis with Copaxone (COP) Elispot assay detects COP-induced interleukin-4 and interferon-γ response in blood cells
26. Long term therapy with glatiramer acetate in multiple sclerosis: Effect on T-cells
27. General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids
28. Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106
29. Copolymer 1 induces T cells of the T helper type 2 that cross-react with myelin basic protein and suppress experimental autoimmune encephalomyelitis
30. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
31. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis